| Identification | Back Directory | [Name]
5H-Pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide, N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-6,7-dihydro- | [CAS]
2238819-65-1 | [Synonyms]
NLRP3-IN-19
5H-Pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide, N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-6,7-dihydro- | [Molecular Formula]
C19 H22 N4 O4 S | [MOL File]
2238819-65-1.mol | [Molecular Weight]
402.47 |
| Hazard Information | Back Directory | [Uses]
JT001 (NLRP3-IN-19) is a potent, specific and orally active inhibitor of NLRP3. JT001 can inhibit NLRP3 inflammasome assembly, resulting in the inhibition of cytokine release and the prevention of pyroptosis. JT001 can be used for the research of nonalcoholic steatohepatitis and liver fibrosis[1]. | [IC 50]
NLRP3 | [References]
[1] Povero D, et, al. Domain-Containing Protein 3 (NLRP3) Inflammasome that Attenuates Development of Nonalcoholic Steatohepatitis and Liver Fibrosis. J Pharmacol Exp Ther. 2023 Aug;386(2):242-258. DOI:10.1124/jpet.123.001639 |
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
| Company Name: |
ChemOrigin Pharm
|
| Telephone: |
15026428026 19002516454 |
| Website: |
www.chemorigin.com |
|